PureTech Health plc — M&A Activity 2022

Oct 11, 2022

6-K 1 d288770d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October, 2022

Commission File Number 001-39670

PURETECH HEALTH PLC

(Translation of registrant’s name into English)

6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On October 11, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) and Nektar Therapeutics, Inc. (“Nektar”) each issued a press release, in accordance with the UK City Code on Takeovers and Mergers, regarding the mutual termination of discussions related to a possible business combination.

The press release issued by the Company is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. The press release issued by Nektar is furnished herewith as Exhibit 99.2 and is incorporated by reference herein.

Exhibits

99.1	Press Release of PureTech Health plc, dated October 11, 2022, titled “Statement regarding termination of discussions with Nektar Therapeutics (“Nektar”).”
99.2	Press Release of Nektar Therapeutics, Inc., dated October 11, 2022, titled “Rule 2.8
Announcement.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ Daphne Zohar
Name:	Daphne Zohar
Title:	Chief Executive Officer